Impact of tumor angiogenesis in peritoneal mesothelioma after radical cytoreduction and hyperthermic intraperitoneal chemotherapy

Pathology and Oncology Research

Volumn 16, Issue 2, 2010, Pages 217-222

  Chua, Terence C ^a   Yao, Peng ^a   Akther, Javed ^a   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Angiogenesis; CD 31 Antigen; Cytoreductive surgery; Mesothelioma; Vascular Endothelial Growth Factor

Indexed keywords

CD31 ANTIGEN; CISPLATIN; DOXORUBICIN; MONOCLONAL ANTIBODY; PARAFFIN; VASCULOTROPIN C;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; OVERALL SURVIVAL; PERITONEUM MESOTHELIOMA; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TUMOR VASCULARIZATION;

ADULT; AGED; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRALESIONAL; KAPLAN-MEIERS ESTIMATE; MALE; MESOTHELIOMA; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PERITONEAL NEOPLASMS; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77955710024     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12253-009-9210-9     Document Type: Article

References (28)

1. Chua TC, Yan TD, Morris DL (2009) Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Can J Surg 52(1):59-64
2. Musk AW, de Klerk NH (2004) Epidemiology of malignant mesothelioma in Australia. Lung Cancer 45(Suppl 1):S21-S23
3. Edwards JG, Swinson DEB, Jones JL, Muller S, Waller DA, O'Byrne KJ (2003) Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 124(5):1916-1923
4. Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL et al. (2003) Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 104 (5):603-610
5. Edwards JG, Cox G, Andi A, Jones JL, Walker RA, Walker DA et al. (2001) Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 85(6):863-868
6. Demirag F, Unsal E, Yilmaz A, Caglar A (2005) Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest 128(5):3382-3387
7. Kothmaier H, Quehenberger F, Halbwedl I, Morbini P, Demirag F, Zeren H et al. (2008) EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors. Thorax 63(4):345-351
8. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G et al. (2001) Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193 (4):468-475 (Pubitemid 32266815)
9. Konig JE, Tolnay E, Wiethege T, Muller KM (1999) Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma. Virchows Arch 435(1):8-12
10. Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M et al. (1999) VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81(1):54-61
11. Ellis LM, Fidler IJ (1996) Angiogenesis and metastasis. Eur J Cancer 32A(14):2451-2460
12. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011-1027
13. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K (2002) Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2 (8):573-583
14. Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S et al. (2008) Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26(10):1698-1704
15. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M et al. (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23(28):6881-6889
16. Yan TD, Welch L, Black D, Sugarbaker PH (2007) A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18(5):827-834 (Pubitemid 47054078)
17. Zellos L, Richards WG, Capalbo L, Jaklitsch MT, Chirieac LR, Johnson BE et al. (2009) A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 137(2):453-458
18. Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29-42
19. Jacquet P, Sugarbaker PH (1996) Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 15:49-58
20. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z et al. (2006) TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 103 (27):10397-10402
21. Carbone M, Kratzke RA, Testa JR (2002) The pathogenesis of mesothelioma. Semin Oncol 29(1):2-17
22. Ault JG, Cole RW, Jensen CG, Jensen LC, Bachert LA, Rieder CL (1995) Behavior of crocidolite asbestos during mitosis in living vertebrate lung epithelial cells. Cancer Res 55(4):792-798
23. Topov J, Kolev K (1987) Cytology of experimental mesotheliomas induced with crocidolite asbestos. Acta Cytol 31(3):369-373
24. Craighead JE, Akley NJ, Gould LB, Libbus BL (1987) Characteristics of tumors and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats. Am J Pathol 129(3):448-462
25. Manning CB, Cummins AB, Jung MW, Berlanger I, Timblin CR, Palmer C et al. (2002) A mutant epidermal growth factor receptor targeted to lung epithelium inhibits asbestos-induced proliferation and proto-oncogene expression. Cancer Res 62(15):4169-4175
26. Zanella CL, Posada J, Tritton TR, Mossman BT (1996) Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res 56(23):5334-5338
27. Gazdar AF, Carbone M (2003) Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin Lung Cancer 5(3):177-181
28. Aoe K, Hiraki A, Tanaka T, Gemba K-I, Taguchi K, Murakami T et al. (2006) Expression of vascular endothelial growth factor in malignant mesothelioma. Anticancer Res 26(6C):4833-4836